cuprins - Gr.T. Popa

REZUMAT – TEZA DE DOCTORAT
29. Frim D.M., Gupta N., Pediatric neurosurgery, Landes Bioscience, 2006
30. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P: Grading of astrocytomas: A simple and
reproducible method, Cancer 62:2152, 1988
31. Hegi M.E., Diserens A., Gorlia T., et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. New Engl J Med 352:997, 2005
32. Stupp R., Mason W., Van den Bent M., et al: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. New Engl.J Med 352:987, 2005.
33. Van den Bent M.J., Afra D., de Witte O., et al: Long-term efficacy of early versus delayed
radiotherapy for low-grade astrocytoma and oligodendroglioma in adults; the EORTC 22845
randomised trial. Lancet 366:985, 2005.
34. Reifenberger G., Louis D.N.: Oligodendroglioma: Toward molecular definitions in diagnostic neurooncology.
J Neuropath Exp Neurol 62:111, 2003
35. Karim A.B., Cornu P., Bleehen N. et al. Immediate postoperative radiotherapy in low grade glioma
improves progression free survival, but not overall survival: preliminary results of an EORTC/MRC
randomized phase III study (abstract). Proc Am Soc Clin Oncol1998;17:400a.
36. Cairncross G., Macdonald D., Ludwin S. et al. Chemotherapy for anaplastic oligodendroglioma. J
Clin Oncol1994;12(10):2013–21.
37. Paleologos N.A., G C.J.. Treatment of oligodendroglioma: an update. Neuro-oncology
1999;1(1):61–8.
38. Olson J.D., Riedel E., DeAngelis L.M., Long-term outcome of low-grade oligodendroglioma and
mixed glioma. Neurology 2000;54:1442–8. 2003.
39. Tzika M.K., Zarifi L., Goumneruva L.G., Astrakas D., Zarakowski T., Young-Poussaint T et al.,
Black neuroimaging in pediatric tumors: Gd-DTPA-enhanced, hemodynamic, and diffusion MR
imaging compared with MR spectroscopic imaging, AJNR AM J Neuroradiol, 2002:23:322.
40. Sarkar C., Sharma M.C., Galkwad S., Sharma C., Singh V.P., Choroid plexis papilloma: a clinical
pathological study of 23 cases. Surg Neurol 1999:52:37
41. Laurence K.M., Hoare R.D., Till K.: The diagnosis of choroid plexus papilloma of the lateral
ventricle. Brain 84:628, 1961.
42. Levine A.J.: Tumor suppressor genes, in Levine A.J., Schmidek H.H. (eds): Molecular Genetics of
Nervous System Tumors. New York, Wiley-Liss,1993:137:143.
43. Seizinger B.R., Roulean G.A., Ozelius L.J., et al: Von Hippel–Lindau disease maps to the region of
chromosome 3 associated with renal carcinoma. Nature 332:268, 1988.
44. Samuels, Martin A., Manual of Neurologic Therapeutics, Lippincott Wiliams&Wilkins, 2004
45. Tsementzis S.A., Differential Diagnosis in Neurology and Neurosurgery, A Clinician’s Pocket
Guide, Thieme 2000
46. Hochberg F.H., Miller D.C., Primary central nervous system lymphoma, J Neurosurg 1988; 68:835–
53.
47. Goldstein J.D., Dickson D.W., Moser F.G. et al. Primary central nervous system lymphoma in
acquired immune deficiency syndrome: a clinical and pathologic study with results of treatment with
radiation. Cancer 1991;67:2756–65.
48. Bessell E.M., Punt J., Firth J. et al. Primary Non-Hodgkin’s lymphoma of the central nervous system:
Phase II study of chemotherapy (BVAM) prior to radiotherapy. Clin Oncol 1991;3:193–8.
49. Liang B.C., Grant R., Junck L. et al. Primary central nervous system lymphoma: treatment with
multiagent systemic and intrathecal chemotherapy with radiation therapy. Int J Oncol 1993;3:1001–
4.
50. Cushing H., Eisenhardt L., Meningiomas. Their classification, regional behavior, life history and
surgical ends results. Springfield, IL: Charles Thomas, 1938